Hong Kong Airlines Stock News

HBM Holdings released its H1 2026 earnings on 13 September 2026, updating investors on the group’s operating performance and financial position for the first half of the year. Management commentary during the earnings call provided additional detail on how current cost pressures and demand conditions are affecting HBM Holdings’ core businesses. This article examines how HBM Holdings’ investment narrative could be influenced by the new information on first half operating performance. Compare...

As Asian markets navigate a landscape marked by fluctuating energy prices and evolving monetary policies, investors are increasingly seeking opportunities in stocks that might be undervalued relative to their intrinsic worth. In this context, identifying stocks that are trading below their estimated fair value can offer potential for growth, particularly as regional economies continue to adapt to global economic shifts.

Cathay Pacific Airways (SEHK:293) has given investors fresh data to chew on after publishing unaudited traffic figures for August 2026. The update details passenger volumes, cargo activity, and load factors across both Cathay Pacific and HK Express. At a share price of HK$14.13, Cathay Pacific Airways has logged an 18.64% 90-day share price return and an 11.88% year-to-date share price gain. The 1-year total shareholder return of 45.36% and 5-year total shareholder return of 169.66% highlight...

Why Ascentage Pharma Group International Is Back On Investor Radars Ascentage Pharma Group International (SEHK:6855) has moved into focus after agreeing to a research collaboration in hematologic oncology with Peking University, tying its cancer pipeline more closely to academic and clinical resources. At a HK$31.7 share price, Ascentage Pharma Group International has seen a sharp 1-day share price return of 7.24%, which contrasts with a weaker year-to-date share price return. The 1-year...

Sun Hung Kai Properties reported full year 2026 sales of HK$94,194 million and net income of HK$21,426 million, alongside a proposed final dividend of HK$2.93 per share for approval at the November 2026 AGM. The proposed dividend, slightly above the prior year’s HK$2.80 per share, reflects management’s stated confidence in cash generation and long term capital return discipline. We will examine how Sun Hung Kai Properties' investment narrative is influenced by reported earnings and the...

Nexteer Automotive Group was removed from the FTSE All-World Index in September 2026, a benchmark tracked by a wide range of global investors. This index exit can affect how much Nexteer Automotive Group features in passive portfolios, which matters for liquidity, ownership mix, and how management thinks about capital markets access. We will now assess how Nexteer Automotive Group's index removal could reshape the existing investment narrative built around electrification and by-wire...

Brilliance China Automotive Holdings was removed from the FTSE All-World Index after the latest review, an index change that occurred before 21 September 2026 and directly affects its inclusion in many global equity benchmarks. This exit from a widely tracked index can matter for Brilliance China Automotive Holdings because passive funds linked to that benchmark may need to rebalance, which can influence liquidity and the investor mix around the stock. We will now look at how Brilliance...

Crystal International Group reported stronger interim profit and an interim dividend for the first half of 2026, supported by healthier apparel demand and tighter operational controls. The business has also strengthened its internal processes after a factoring disclosure lapse, which may influence how investors view its earnings quality and risk controls. This article explores how Crystal International Group's investment narrative is shaped by stronger interim profitability and higher...

Hansoh Pharmaceutical Group reported that HS-10374, its self-developed selective TYK2 inhibitor, met co-primary and multiple secondary endpoints in a pivotal Phase III trial in adults with moderate-to-severe plaque psoriasis. The trial showed higher PASI 75 and sPGA 0/1 response rates than placebo, no new safety signals, and the company now plans to prepare a new drug application in China. The psoriasis data indicate that HS-10374 could extend Hansoh Pharmaceutical Group's reach into chronic...

Yangtze Optical Fibre And Cable Joint Stock Limited Company approved an interim dividend of RMB 10.60 per 10 shares for the first half of 2026, totaling about RMB 877,579,414, with H share holders generally receiving HKD 12.26 per 10 shares based on a fixed exchange rate calculation. The detailed dividend structure, including currency conversion terms and a defined entitlement date, highlights how Yangtze Optical Fibre And Cable manages capital returns between domestic and H share...

China Coal Energy (SEHK:1898) came back into focus after its September 11 update showed lower year on year commercial coal and self produced coal volumes, while several chemical product lines reported higher monthly and year to date tonnages. Recent trading shows that China Coal Energy’s share price has drifted over the past month and quarter, with a 30 day share price return of 3.22% lower and a 90 day share price return of 1.19% lower. This comes even as the year to date share price return...

China Power International Development entered into a multi year Framework Agreement with State Power Investment Corporation Limited Group in September 2026 to supply environmental protection engineering services and related products, with proposed annual caps of RMB 700,000,000 for late 2026 and RMB 1,450,000,000 for 2027 and 2028. The agreement formalizes a broad service scope from coal fired plant upgrades to carbon capture projects. This indicates that environmental services are becoming...

Industrial and Commercial Bank of China (SEHK:1398) just wrapped up a RMB 20b issuance of undated Additional Tier 1 capital bonds, giving the lender fresh regulatory capital and added financial flexibility. The fresh Additional Tier 1 capital comes as Industrial and Commercial Bank of China’s HK$7.58 share price sits on a year to date share price return of 19.56%, with a 90 day share price gain of 8.91% and a 1 year total shareholder return of 39.24%. This hints that investors have been...

XTransfer’s new cooperation with China Zheshang Bank (SEHK:2016) on all currency settlement and minor currency collection puts cross border payment plumbing at center stage for anyone tracking the stock. The cooperation lands while China Zheshang Bank’s 30 day share price return of 6.78% and 90 day share price return of 6.09% point to improving short term momentum, even though the year to date share price return declined 3.56% and the 1 year total shareholder return declined 1.48%. This...

Genscript Biotech announced that it joined Eli Lilly's TuneLab AI-enabled drug discovery platform, agreeing to provide preferred-rate wet lab services that turn AI predictions into biological data, in line with its integrated R&D support strategy. The TuneLab agreement embeds Genscript Biotech directly into AI-driven discovery workflows, which could influence future demand, capacity planning, and pricing power across its lab services portfolio. We will now assess how Genscript Biotech's...

Vobile Group officially launched the SeeBay platform on 17 September 2026, positioning it as a one stop hub for AI content creation and global IP monetization, with over 20,000 registered users and more than 13,600 content creation tasks recorded so far. The collaboration agreement between a Vobile Group subsidiary and Ant Blockchain Technology to build a copyright large model signals a push to hardwire IP protection and rights management into AI driven content workflows. This development...

Index Exit Puts United Energy Group in Focus United Energy Group (SEHK:467) has been removed from the FTSE All-World Index in its USD version, an index change that can affect passive fund flows and institutional visibility. United Energy Group’s HK$0.42 share price has moved higher over the past month, with a 30-day share price return of 9.09% and a 90-day gain of 16.67%. However, the year-to-date share price return is down 10.64% and the 1-year total shareholder return has fallen 22.22%...

Yue Yuen Industrial (Holdings) (SEHK:551) has reported unaudited figures for August, with net consolidated operating revenue of US$636.647m for the month and US$5.217b for the year to date. The latest revenue update lands as Yue Yuen Industrial (Holdings) trades at HK$12.4, with the share price down 10.6% over the past 30 days and 22.35% year to date, even though the 3 year total shareholder return of 78.57% points to a much stronger longer run outcome than the recent pullback...

CK Asset Holdings (SEHK:1113) has attracted fresh attention after its recent close at HK$46. The move comes against a backdrop of mixed short term returns and double digit gains over the past year. Short term momentum for CK Asset Holdings has cooled, with the share price down over the past week and month. However, the 90 day share price return remains in positive territory and a 1 year total shareholder return of 29.92% still point to stronger longer term gains. Scan beyond CK Asset Holdings...

Sun Art Retail Group (SEHK:6808) was recently removed from the FTSE All-World Index, a move that can prompt forced selling by index-tracking funds and reshape how investors view liquidity and visibility. Recent share price performance around HK$1.06 has been choppy, with a 1-day share price return of 2.91% and a 90-day share price return of 3.92%. However, the year-to-date share price return has fallen 39.08% and the 1-year total shareholder return is down 40.09%. This points to fading...

Chervon Holdings (SEHK:2285) just made a sweeping leadership change that puts long time power tool executive Joseph Galli Jr. in the CEO seat, with Jeffrey P. Campbell stepping in to guide industrial and commercial sales. The leadership reshuffle comes at a time when Chervon Holdings’ shares have picked up momentum, with a 30 day share price return of 23.53% and a 90 day gain of 57.50% from a latest close of HK$25.2. The 1 year total shareholder return of 16.53% points to a more measured...

Sino Biopharmaceutical presented preclinical data for TQH5528, an oral STAT6 degrader from its OAPD platform, at the European Respiratory Society 2026 Congress. The data highlighted activity on the IL-4/IL-13/STAT6 axis and convenient oral dosing potential versus injectable biologics. The program features a novel CRBN ligand, picomolar STAT6 degradation and favourable oral exposure across species. Taken together, these attributes point to meaningful R&D investment around a differentiated...

WuXi XDC Cayman (SEHK:2268) is back in focus after announcing an exclusive global out licensing deal with Ona Therapeutics for its WuXiTecan-2 payload linker technology platform. The licensing update comes on top of a strong run in WuXi XDC Cayman’s stock. The latest share price is HK$80.7 after a 1-day share price return of 4.81% and a 90-day share price return of 65.17%. This performance far outpaces its 1-year total shareholder return of 5.84%, suggesting that momentum has picked up...

CSPC Pharmaceutical Group (SEHK:1093) has been busy. A fresh Phase II trial in type 2 diabetes, new NMPA designations in oncology and multiple trial approvals across neurology and ophthalmology are drawing fresh attention to the shares. The recent cluster of diabetes, oncology, neurology and ophthalmology updates appears to have coincided with a sharp pickup in interest. CSPC Pharmaceutical Group’s 1-day share price return of 7.56% at HK$9.605 capped a 90-day share price return of 40.42%,...